{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-022852","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.953540+00:00","generated_at":"2026-06-15T19:51:26.724504+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Insmed Q1 revenue up 23% to $65.2M; net loss widens to $159.8M; pipeline on track","bullets":["ARIKAYCE global revenue $65.2M, up 23% YoY; U.S. net sales $49.1M, Japan $13.2M.","Net loss $159.8M ($1.17/share) vs $94.6M ($0.80) in Q1 2022; R&D spend rose to $127.9M.","Cash and securities $999M at March 31, 2023, down from $1.15B at Dec 31, 2022.","Phase 3 ASPEN enrollment completed (1,700+ patients); topline data expected Q2 2024.","Reaffirmed FY2023 ARIKAYCE revenue guidance $285M-$300M; appointed Makoto Nakamura GM Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-022852","json":"https://secwatch.observer/filing/0001140361-23-022852.json","markdown":"https://secwatch.observer/filing/0001140361-23-022852.md","text":"https://secwatch.observer/filing/0001140361-23-022852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123022852/0001140361-23-022852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123022852/brhc20052467_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T19:51:26.724504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a5d515f7c05b7db137b82422d5095cf8d9dfab4","claim":"INSMED Inc reported the first quarter ended March 31, 2023 results: revenue $65.2 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue for the first quarter ended March 31, 2023, was $65.2 million, reflecting 23% year-over-year growth compared to total revenue of $53.1 million for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1104506/000114036123022852/0001140361-23-022852-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$65.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}